A new study published in Neurology, has shown that long-term inflammation in older patients with diabetes can also hasten their cognitive decline.
Inflammation, the body's defence mechanism against injury and infection, can also lead to the development of insulin resistance and diabetes. Research has shown that a vicious cycle ensues, with insulin resistance leading to increased inflammation.
type 2 diabetes mellitus (T2DM)
Now, a new study published in Neurology, has shown that long-term inflammation in older patients with diabetes can also hasten their cognitive decline. The study authors followed 65 patients with , evenly split in both genders and an average of 66 years old, to evaluate the relationships between inflammation, cerebral vasoregulation, and cognitive decline in T2DM. When the trial participants were evaluated at 2 years, a diminished global and regional cerebral vasoreactivity was observed, along with a decline in multiple cognitive tasks compared with their baseline activity at the beginning of the study, the authors write. Additionally, the authors noted that high levels of serum soluble intercellular and vascular adhesion molecules, higher cortisol, and higher C-reactive protein levels were associated with greater decreases in cerebral vasoreactivity and vasodilation in the T2DM group.
according to study author Vera Novak, MD, PhD, of Harvard Medical School in Boston.
Their findings led to the conclusion that inflammation may further impair cerebral vasoregulation, which in turn hastens decline in executive function and daily activities that the older diabetic population performs.
Source: ScienceDaily
"Normal blood flow regulation allows the brain to redistribute blood to areas of the brain that have increased activity while performing certain tasks. People with type 2 diabetes have impaired blood flow regulation. Our results suggest that diabetes and high blood sugar impose a chronic negative effect on cognitive and decision-making skills,"
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More